Principal Investigator

Geneviève Deblois

Metabolic and Epigenetic Alterations in Cancer

Subscribe to the newsletter

Geneviève Deblois and her team aim to better understand the development of drug resistance in cancers, particularly in triple negative breast cancer. They study changes in cell metabolism that contribute to the development of resistance to treatments by modifying the epigenetic profile of cancer cells.

Principal Investigator, Metabolic and Epigenetic Alterations in Cancer Research Unit, IRIC

Assistant Professor, Faculty of Pharmacy, Université de Montréal

Metabolic and Epigenetic Alterations in Cancer Unit

Marcelle-Coutu Pavilion, 3306-17

Phone (office)
(514) 343-6111, ext. 0617
Fax
(514) 343-7780
Email
genevieve.deblois@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Publications

  • December 14, 2023

    Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance.

    Kohan AA, Lupien M, Cescon D, Deblois G, Ventura M, Metser U, Veit-Haibach P
    Eur J Nucl Med Mol Imaging 2023-12-14 ;

  • April 5, 2023

    Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.

    Cameron S, Deblois G, Hawley JR, Qamra A, Zhou S, Tonekaboni SAM, Murison A, Van Vliet R, Liu J, Locasale JW, Lupien M
    Oncogene 2023-04-05 ;

  • January 1, 2023

    Profiling the Epigenetic Landscape of the Tumor Microenvironment Using Chromatin Immunoprecipitation Sequencing.

    Fukano M, Alzial G, Lambert R, Deblois G
    Methods Mol Biol 2023-01-01 ;2614:313-348

  • September 6, 2022

    3D chromatin remodeling potentiates transcriptional programs driving cell invasion.

    Lebeau B, Jangal M, Zhao T, Wong CK, Wong N, Cañedo EC, Hébert S, Aguilar-Mahecha A, Chabot C, Buchanan M, Catterall R, McCaffrey L, Deblois G, Kleinman C, Park M, Basik M, Witcher M
    Proc Natl Acad Sci U S A 2022-09-06 ;119( 36 ):e2203452119

  • See all publications

Awards and distinctions

  • Project Grant - Canadian Institutes of Health Research, 2021-2026